DNTH Stock Analysis: Buy, Sell, or Hold?
DNTH - Dianthus Therapeutics, Inc. Common Stock
$106.92
-5.72 (-5.08%)
▼
5d:
+2.94%
30d:
+18.52%
90d:
+21.78%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Get Alerted When DNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DNTH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DNTH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DNTH is currently trading at $106.92, which is considered extended relative to its 30-day fair value range of $94.21 to $104.96.
Technical Outlook: Technically, DNTH is in a uptrend. Immediate support is located at $100.00, while resistance sits at $114.55. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: DNTH has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $128.58 (+20.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DNTH is in a uptrend. Immediate support is located at $100.00, while resistance sits at $114.55. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: DNTH has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $128.58 (+20.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$94.21 -
$104.96
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 20.3% below Wall St target ($128.58)
Trading Range Analysis
30-Day Trading Range
$94.21 -
$104.96
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$9.77
(9.1%)
Support & Resistance Levels
Support Level
$100.00
Resistance Level
$114.55
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.99
Wall Street Target
$128.58
(+20.3%)
Revenue Growth (YoY)
-60.2%
Share & Embed Analysis
Last updated: August 02, 2026 8:09 PM ET
Data refreshes hourly during market hours. Next update: 9:09 PM
Data refreshes hourly during market hours. Next update: 9:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Ryan Savitz
SELL
8224 shares
2026-04-09
Ryan Savitz
SELL
114367 shares
2026-03-31
Edward Carr
SELL
43682 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced DNTH Option Strategies
Professional options setups generated by AI based on today's DNTH price and gamma walls.
